ActiGraph Announces New Scientific Affairs and Data Management Division

Aug 14, 2018 - Pensacola, FL - ActiGraph, the leading provider of medical-grade wearable activity and sleep monitoring solutions for the global scientific community, announced today the establishment of a new Scientific Affairs and Data Management division.  A primary focus of this new division is to foster and support scientific collaborations with ActiGraph’s academic and pharmaceutical industry partners to advance the development of meaningful clinical trial endpoints based on high-resolution raw accelerometry data.

Guided by the novel endpoint development framework released by the Clinical Trials Transformation Initiative (CTTI) in 2017, ActiGraph’s Scientific Affairs and Data Management division, headed by Director Tyler Guthrie, will facilitate joint research and development projects involving corporate partners and subject matter experts from within the company’s global network of over 1000 academic partners. With extensive accelerometry experience in a wide variety of specific chronic disease populations, ActiGraph’s academic subject matter experts bring a wealth of practical knowledge and analytic expertise to projects exploring new meaningful clinical endpoints and better ways to measure existing endpoints using accelerometry. ActiGraph is also exploring additional partnerships to develop clinical endpoints based on new methods, including artificial intelligence (AI) and machine learning.

“The Scientific Affairs and Data Management division was formed as a direct response to the growing need from pharmaceutical sponsors and CROs for scientifically validated digital endpoints,” said Jeff Arnett, ActiGraph CEO. "We have already been tapping into the expertise of our academic subject matter experts and internal scientific team for existing clinical trial projects. By establishing this focused division, we can accelerate the development, validation, and implementation of novel digital clinical endpoints that could improve future trials.”

ActiGraph’s announcement comes at a time when the use of digital tools to capture quantifiable measures of biology and health is rapidly increasing across the clinical trials landscape. “We are delighted that pioneering companies like ActiGraph are helping lead the way in the development and application of digital biomarkers to a wide range of clinical conditions,” said E. Ray Dorsey, M.D., Editor-and-Chief for the Digital Biomarkers scientific journal.

ActiGraph’s establishment of the Scientific Affairs and Data Management division precedes the upcoming launches of two new products within its clinical trials technology ecosystem. In August 2018, the company will release CentrePoint 3.0, a major update to its software platform that includes highly anticipated raw data analytic capabilities. In late Q3 2018, ActiGraph will launch the patient-centric CentrePoint Insight Watch, a triaxial accelerometry watch with a 30-day battery life, designed specifically for use in clinical drug trials. The CentrePoint Insight Watch captures continuous, high-resolution raw acceleration data and supports near real-time remote patient monitoring when used in combination with ActiGraph’s CentrePoint home data hub or mobile application.

About ActiGraph

ActiGraph is the leading provider of medical-grade physical activity and sleep monitoring solutions for the global scientific community. ActiGraph’s wearable actigraphy monitors and robust analytics platform have been widely used to quantify human movement in academic and population health research for nearly two decades. In recent years, the company’s monitoring solutions have been steadily adopted by biopharma and life sciences organizations seeking to capture real-world objective outcomes related to physical activity, mobility, and sleep behavior for patients enrolled in clinical trials.

xxxx

Back to news